NO20092331L - LINGO-bindingsmolekyler og farmasoytisk anvendelse derav - Google Patents

LINGO-bindingsmolekyler og farmasoytisk anvendelse derav

Info

Publication number
NO20092331L
NO20092331L NO20092331A NO20092331A NO20092331L NO 20092331 L NO20092331 L NO 20092331L NO 20092331 A NO20092331 A NO 20092331A NO 20092331 A NO20092331 A NO 20092331A NO 20092331 L NO20092331 L NO 20092331L
Authority
NO
Norway
Prior art keywords
binding molecule
lingo
polynucleotide
binding molecules
pharmaceutical use
Prior art date
Application number
NO20092331A
Other languages
English (en)
Norwegian (no)
Inventor
Josef Prassler
Adrien Walmsley
William Leonard Wishart
Marta Cortes-Cros
Ingo Klagge
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38325542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092331(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092331L publication Critical patent/NO20092331L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20092331A 2006-11-17 2009-06-17 LINGO-bindingsmolekyler og farmasoytisk anvendelse derav NO20092331L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124350 2006-11-17
PCT/EP2007/009880 WO2008058736A1 (en) 2006-11-17 2007-11-15 Lingo binding molecules and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
NO20092331L true NO20092331L (no) 2009-06-17

Family

ID=38325542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092331A NO20092331L (no) 2006-11-17 2009-06-17 LINGO-bindingsmolekyler og farmasoytisk anvendelse derav

Country Status (27)

Country Link
US (4) US8299221B2 (de)
EP (2) EP2084190B1 (de)
JP (2) JP5647414B2 (de)
KR (1) KR20090078353A (de)
CN (2) CN101553506B (de)
AR (1) AR063829A1 (de)
AT (1) ATE502960T1 (de)
AU (1) AU2007321817A1 (de)
BR (1) BRPI0718406A2 (de)
CA (1) CA2669181A1 (de)
CL (1) CL2007003303A1 (de)
CO (1) CO6180433A2 (de)
CR (1) CR10756A (de)
DE (1) DE602007013445D1 (de)
EC (1) ECSP099332A (de)
ES (1) ES2363622T3 (de)
GT (1) GT200900121A (de)
IL (1) IL198313A0 (de)
MA (1) MA30965B1 (de)
MX (1) MX2009005175A (de)
NO (1) NO20092331L (de)
PE (1) PE20081392A1 (de)
RU (1) RU2009122514A (de)
TN (1) TN2009000190A1 (de)
TW (1) TW200831534A (de)
WO (1) WO2008058736A1 (de)
ZA (1) ZA200902409B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2519227C (en) 2003-03-19 2013-12-03 Biogen Idec Ma Inc. Nogo receptor binding protein
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
HRP20131066T1 (hr) 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba
JP5312039B2 (ja) * 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
EP2068866A4 (de) 2006-07-24 2010-04-07 Biogen Idec Inc Verfahren zur förderung von myelinisierung, neuronalem überleben und oligodendrozytendifferenzierung mittels verabreichung von sp35- bzw. trka-antagonisten
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (de) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von isoleucyl-trna-synthetasen
AU2011248521B2 (en) 2010-04-27 2017-03-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl tRNA synthetases
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2566516B1 (de) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Innovative entdeckung von therapeutischen und diagnostischen mitteln sowie antikörperzusammensetzungen im zusammenhang mit proteinfragmenten von seryl-trna-synthetasen
CN103096909A (zh) 2010-05-04 2013-05-08 Atyr医药公司 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (de) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
KR20130102534A (ko) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
KR20180059575A (ko) 2010-07-12 2018-06-04 에이티와이알 파마, 인코포레이티드 아스파르틸­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103118696B (zh) 2010-10-06 2020-02-14 Atyr 医药公司 与色氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
CA2858613A1 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
EP2806948B1 (de) 2012-01-27 2020-01-15 New York University Verfahren zur verbesserung von remyelinisierung unter verwendung von gli1-inhibitoren
KR102142161B1 (ko) * 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
WO2016122761A1 (en) * 2015-01-26 2016-08-04 Intel IP Corporation Device and method to improve horizontal and vertical positioning accuracy
KR20190039134A (ko) * 2016-07-13 2019-04-10 바이오젠 엠에이 인코포레이티드 Lingo-1 길항제의 투약 섭생 및 탈수초성 질환의 치료를 위한 용도
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
KR102414826B1 (ko) 2020-06-18 2022-06-30 삼성전기주식회사 코일 부품

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (de) 1986-09-02 1993-03-31 Enzon Labs Inc. Bindungsmoleküle mit einzelpolypeptidkette
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2085326T3 (es) 1989-02-13 1996-06-01 Schering Ag Activador de plasminogeno salivar del murcielago vampiro vpa-alfa1.
CN1798840B (zh) * 2003-03-19 2010-11-10 比奥根艾迪克Ma公司 Nogo受体结合蛋白
CA2519227C (en) 2003-03-19 2013-12-03 Biogen Idec Ma Inc. Nogo receptor binding protein
US20050214288A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
US8486893B2 (en) * 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
HRP20131066T1 (hr) 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba

Also Published As

Publication number Publication date
US20130071400A1 (en) 2013-03-21
ES2363622T3 (es) 2011-08-10
BRPI0718406A2 (pt) 2013-12-17
KR20090078353A (ko) 2009-07-17
JP5647414B2 (ja) 2014-12-24
TN2009000190A1 (en) 2010-10-18
CN101553506B (zh) 2013-08-07
US20140037639A1 (en) 2014-02-06
US20140255415A1 (en) 2014-09-11
US8299221B2 (en) 2012-10-30
RU2009122514A (ru) 2010-12-27
EP2395022A1 (de) 2011-12-14
JP2013056888A (ja) 2013-03-28
IL198313A0 (en) 2011-08-01
EP2084190B1 (de) 2011-03-23
AR063829A1 (es) 2009-02-18
ZA200902409B (en) 2010-04-28
CA2669181A1 (en) 2008-05-22
ECSP099332A (es) 2009-06-30
CO6180433A2 (es) 2010-07-19
MX2009005175A (es) 2009-08-07
EP2084190A1 (de) 2009-08-05
CN103351437A (zh) 2013-10-16
TW200831534A (en) 2008-08-01
US20100143362A1 (en) 2010-06-10
AU2007321817A1 (en) 2008-05-22
MA30965B1 (fr) 2009-12-01
PE20081392A1 (es) 2008-11-12
CL2007003303A1 (es) 2008-06-27
CR10756A (es) 2009-06-04
CN101553506A (zh) 2009-10-07
GT200900121A (es) 2011-11-11
EP2395022A9 (de) 2013-04-24
JP2010509906A (ja) 2010-04-02
WO2008058736A1 (en) 2008-05-22
ATE502960T1 (de) 2011-04-15
DE602007013445D1 (de) 2011-05-05

Similar Documents

Publication Publication Date Title
NO20092331L (no) LINGO-bindingsmolekyler og farmasoytisk anvendelse derav
WO2022026475A3 (en) Multimeric coronavirus binding molecules and uses thereof
BRPI0511479A (pt) molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
BRPI0614761A2 (pt) proteìnas de fusão de albumina
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
WO2006032436A3 (en) Use of microproteins as tryptase inhibitors
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
WO2007054520A3 (en) Methods for the identification of microrna and their applications in research and human health
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011097181A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
WO2009152480A3 (en) Methods to treat solid tumors
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
MY149546A (en) Improved nogo-a binding molecules and pharmaceutical use tereof
TW200722090A (en) Compounds useful for inhibiting chk1
NO20061678L (no) NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav
WO2010065069A3 (en) Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
WO2010011994A3 (en) Polypeptides and uses thereof
WO2009004632A3 (en) Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
WO2006094813A3 (en) Dimeric or multimeric microproteins
WO2005110460A3 (en) Diagnosis and treatment methods related to aging, especially in muscle (14.1)
WO2006128025A3 (en) Regulatory proteins in lung repair and treatment of lung disease
NO20056005L (no) Terapautiske midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application